Edesa Biotech is trading 8.17% higher at $2.78 in pre-market, with no clear catalyst identified.
- The October 16 close was $2.57.
- No new company announcement dated October 19 was identified. FDA clearance for its Phase 2 vitiligo study was announced October 15, but available evidence does not establish it as the cause of the rise.
- The supplied sector context is bearish.